Literature DB >> 23809378

Glycoprotein IIb-IIIa inhibitors - do we still need them?

Vijayakumar Subban1, K Sarat Chandra.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23809378      PMCID: PMC3861204          DOI: 10.1016/j.ihj.2013.04.032

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


× No keyword cloud information.
  35 in total

1.  Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Authors:  Deepak L Bhatt; Gregg W Stone; Kenneth W Mahaffey; C Michael Gibson; P Gabriel Steg; Christian W Hamm; Matthew J Price; Sergio Leonardi; Dianne Gallup; Ezio Bramucci; Peter W Radke; Petr Widimský; Frantisek Tousek; Jeffrey Tauth; Douglas Spriggs; Brent T McLaurin; Dominick J Angiolillo; Philippe Généreux; Tiepu Liu; Jayne Prats; Meredith Todd; Simona Skerjanec; Harvey D White; Robert A Harrington
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 91.245

2.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

3.  Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines.

Authors:  David E Winchester; Xuerong Wen; William D Brearley; Ki E Park; R David Anderson; Anthony A Bavry
Journal:  J Am Coll Cardiol       Date:  2011-03-08       Impact factor: 24.094

4.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Authors:  Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Franz Dotzer; Jurriën ten Berg; Hildegard Bollwein; Isolde Graf; Maryam Ibrahim; Jürgen Pache; Melchior Seyfarth; Helmut Schühlen; Josef Dirschinger; Peter B Berger; Albert Schömig
Journal:  JAMA       Date:  2006-03-13       Impact factor: 56.272

5.  Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin.

Authors:  Osmar Antonio Centurión
Journal:  Open Cardiovasc Med J       Date:  2010-06-17

6.  The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?

Authors:  Edo Kaluski
Journal:  Curr Cardiol Rev       Date:  2008-05

7.  Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.

Authors:  Annapoorna S Kini; Victor H T Chen; Prakash Krishnan; Paul Lee; Michael C Kim; Angelica Mares; Javed Suleman; Pedro R Moreno; Samin K Sharma
Journal:  Am Heart J       Date:  2008-07-02       Impact factor: 4.749

8.  Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.

Authors:  Anthony Y Fung; Jacqueline Saw; Andrew Starovoytov; Cameron Densem; Percy Jokhi; Simon J Walsh; Rebecca S Fox; Karin H Humphries; Eve Aymong; Donald R Ricci; John G Webb; Jaap N Hamburger; Ronald G Carere; Christopher E Buller
Journal:  J Am Coll Cardiol       Date:  2009-03-10       Impact factor: 24.094

9.  Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.

Authors:  A A C M Heestermans; J W Van Werkum; C Hamm; T Dill; A T M Gosselink; M J De Boer; G Van Houwelingen; J C A Hoorntje; P C Koopmans; J M Ten Berg; A W J Van 't Hof
Journal:  J Thromb Haemost       Date:  2009-08-11       Impact factor: 5.824

Review 10.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

Authors:  Dominick J Angiolillo; Antonio Fernandez-Ortiz; Esther Bernardo; Fernando Alfonso; Carlos Macaya; Theodore A Bass; Marco A Costa
Journal:  J Am Coll Cardiol       Date:  2007-03-26       Impact factor: 24.094

View more
  2 in total

Review 1.  Antiplatelet Therapy in Acute Coronary Syndrome.

Authors:  Kerry Layne; Albert Ferro
Journal:  Eur Cardiol       Date:  2017-08

Review 2.  Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids.

Authors:  Reheman Adili; Megan Hawley; Michael Holinstat
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-09-25       Impact factor: 3.072

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.